# Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

> **NCT06057402** · PHASE4 · RECRUITING · sponsor: **Pfizer** · enrollment: 80 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT06057402
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-03
- **Primary completion:** 2032-02-22
- **Final completion:** 2032-02-22
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057402, "Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT06057402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*